Which has preferable earnings & valuation, EDSA or FBLG?

Edesa Biotech is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.69 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is EDSA or FBLG more profitable?

FibroBiologics' return on equity of -536.78% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% FibroBiologics N/A -536.78% -225.12%

Do analysts prefer FBLG or BYSI?

FibroBiologics currently has a consensus target price of $73.00, suggesting a potential upside of 5,787.10%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FBLG or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% BeyondSpring N/A N/A -28.88%

Does the media prefer FBLG or BYSI?

In the previous week, BeyondSpring had 5 more articles in the media than FibroBiologics. MarketBeat recorded 7 mentions for BeyondSpring and 2 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.32 beat BeyondSpring's score of 0.17 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeyondSpring 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, FBLG or QNCX?

FibroBiologics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$5.19 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is FBLG or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Quince Therapeutics N/A N/A -133.84%

Does the media refer more to FBLG or QNCX?

In the previous week, Quince Therapeutics had 3 more articles in the media than FibroBiologics. MarketBeat recorded 5 mentions for Quince Therapeutics and 2 mentions for FibroBiologics. Quince Therapeutics' average media sentiment score of 0.56 beat FibroBiologics' score of 0.32 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, BRNS or FBLG?

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is BRNS or FBLG more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% FibroBiologics N/A -536.78% -225.12%

FibroBiologics (FBLG) Competitors

$1.24 +0.04 (+2.90%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.17 -0.07 (-5.32%)

As of 10/2/2026 07:55 PM Eastern

Compare

FBLG vs. EDSA, BYSI, QNCX, SGMO, and BRNS

Should you buy FibroBiologics stock or one of its competitors? FibroBiologics's main competitors and comparable companies include Edesa Biotech (EDSA), BeyondSpring (BYSI), Quince Therapeutics (QNCX), Sangamo Therapeutics (SGMO), and Barinthus Biotherapeutics (BRNS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does FibroBiologics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Edesa Biotech is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

FibroBiologics' return on equity of -536.78% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
FibroBiologics	N/A	-536.78%	-225.12%

Edesa Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market.

5.5% of Edesa Biotech shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 7.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 29.53%. FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 5,787.10%. Given FibroBiologics' higher probable upside, analysts plainly believe FibroBiologics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, FibroBiologics had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for Edesa Biotech. FibroBiologics' average media sentiment score of 0.32 beat Edesa Biotech's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
FibroBiologics	Neutral

Summary

Edesa Biotech beats FibroBiologics on 7 of the 13 factors compared between the two stocks.

How does FibroBiologics compare to BeyondSpring?

FibroBiologics (NASDAQ:FBLG) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

40.3% of BeyondSpring shares are held by institutional investors. 7.3% of FibroBiologics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, BeyondSpring had 5 more articles in the media than FibroBiologics. MarketBeat recorded 7 mentions for BeyondSpring and 2 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.32 beat BeyondSpring's score of 0.17 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeyondSpring	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring has higher revenue and earnings than FibroBiologics. BeyondSpring is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
BeyondSpring	$1.75M	18.50	-$1.01M	-$0.12	N/A

FibroBiologics currently has a consensus target price of $73.00, suggesting a potential upside of 5,787.10%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
BeyondSpring	N/A	N/A	-28.88%

FibroBiologics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Summary

BeyondSpring beats FibroBiologics on 8 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to Quince Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

FibroBiologics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

In the previous week, Quince Therapeutics had 3 more articles in the media than FibroBiologics. MarketBeat recorded 5 mentions for Quince Therapeutics and 2 mentions for FibroBiologics. Quince Therapeutics' average media sentiment score of 0.56 beat FibroBiologics' score of 0.32 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FibroBiologics presently has a consensus price target of $73.00, suggesting a potential upside of 5,787.10%. Quince Therapeutics has a consensus price target of $206.71, suggesting a potential upside of 607.93%. Given FibroBiologics' higher possible upside, analysts plainly believe FibroBiologics is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62

FibroBiologics has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

30.8% of Quince Therapeutics shares are owned by institutional investors. 7.3% of FibroBiologics shares are owned by company insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Quince Therapeutics' return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Quince Therapeutics	N/A	N/A	-133.84%

Summary

Quince Therapeutics beats FibroBiologics on 9 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Sangamo Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 5,787.10%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than FibroBiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

FibroBiologics has lower revenue, but higher earnings than Sangamo Therapeutics. FibroBiologics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 7.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

FibroBiologics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. FibroBiologics' return on equity of -536.78% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
FibroBiologics	N/A	-536.78%	-225.12%

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market.

In the previous week, FibroBiologics had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for Sangamo Therapeutics. FibroBiologics' average media sentiment score of 0.32 beat Sangamo Therapeutics' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
FibroBiologics	Neutral

Summary

FibroBiologics beats Sangamo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 7.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Barinthus Biotherapeutics' return on equity of -59.15% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
FibroBiologics	N/A	-536.78%	-225.12%

Barinthus Biotherapeutics presently has a consensus target price of $4.00, indicating a potential upside of 440.47%. FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 5,787.10%. Given FibroBiologics' higher probable upside, analysts plainly believe FibroBiologics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, FibroBiologics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for FibroBiologics and 0 mentions for Barinthus Biotherapeutics. FibroBiologics' average media sentiment score of 0.32 beat Barinthus Biotherapeutics' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
FibroBiologics	Neutral

Barinthus Biotherapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market.

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Summary

Barinthus Biotherapeutics and FibroBiologics tied by winning 6 of the 12 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.26M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-0.24	13.00	274.71	26.04
Price / Sales	N/A	1,288.64	656.46	105.16
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.67	16.57	10.93	6.31
Net Income	-$18.65M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-10.79%	-2.97%	-2.00%	-1.66%
1 Month Performance	-31.49%	-10.82%	-6.19%	-4.68%
1 Year Performance	-88.71%	19.00%	8.03%	1.57%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.0219 of 5 stars	$1.24 +2.9%	$73.00 +5,787.1%	-88.7%	$8.26M	N/A	N/A	15	Short Interest Increase
EDSA Edesa Biotech	1.8428 of 5 stars	$3.56 -2.5%	$5.00 +40.4%	+50.8%	$34.32M	N/A	N/A	17	Positive News
BYSI BeyondSpring	0.1787 of 5 stars	$0.77 -31.0%	N/A	-55.0%	$31.80M	$1.75M	N/A	44	Gap Down High Trading Volume
QNCX Quince Therapeutics	3.8096 of 5 stars	$31.17 +7.5%	$206.71 +563.2%	-91.2%	$31.79M	N/A	N/A	38	News Coverage Analyst Forecast Gap Up
SGMO Sangamo Therapeutics	1.0052 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. EDSA, BYSI, QNCX, SGMO, and BRNS

How does FibroBiologics compare to Edesa Biotech?

Summary

How does FibroBiologics compare to BeyondSpring?

Summary

How does FibroBiologics compare to Quince Therapeutics?

Summary

How does FibroBiologics compare to Sangamo Therapeutics?

Summary

How does FibroBiologics compare to Barinthus Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. EDSA, BYSI, QNCX, SGMO, and BRNS

How does FibroBiologics compare to Edesa Biotech?

Which has preferable earnings & valuation, EDSA or FBLG?

Is EDSA or FBLG more profitable?

Which has more risk and volatility, EDSA or FBLG?

Do insiders & institutionals have more ownership in EDSA or FBLG?

Do analysts rate EDSA or FBLG?

Does the media favor EDSA or FBLG?

Summary

How does FibroBiologics compare to BeyondSpring?

Do insiders & institutionals hold more shares of FBLG or BYSI?

Does the media prefer FBLG or BYSI?

Which has stronger valuation & earnings, FBLG or BYSI?

Do analysts prefer FBLG or BYSI?

Is FBLG or BYSI more profitable?

Which has more volatility & risk, FBLG or BYSI?

Summary

How does FibroBiologics compare to Quince Therapeutics?

Which has better valuation & earnings, FBLG or QNCX?

Does the media refer more to FBLG or QNCX?

Do analysts prefer FBLG or QNCX?

Which has more risk & volatility, FBLG or QNCX?

Do insiders & institutionals hold more shares of FBLG or QNCX?

Is FBLG or QNCX more profitable?

Summary

How does FibroBiologics compare to Sangamo Therapeutics?

Do analysts recommend SGMO or FBLG?

Which has higher valuation and earnings, SGMO or FBLG?

Do institutionals & insiders have more ownership in SGMO or FBLG?

Is SGMO or FBLG more profitable?

Which has more volatility & risk, SGMO or FBLG?

Does the media refer more to SGMO or FBLG?

Summary

How does FibroBiologics compare to Barinthus Biotherapeutics?

Do institutionals and insiders believe in BRNS or FBLG?

Is BRNS or FBLG more profitable?

Do analysts rate BRNS or FBLG?

Does the media favor BRNS or FBLG?

Which has more risk & volatility, BRNS or FBLG?

Which has higher earnings and valuation, BRNS or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools